Back to All Studies

Researchers are conducting a clinical trial to evaluate a promising new immunotherapy to curb cancer metastasis in dogs with osteosarcoma, the most common primary bone tumor in canine patients. The research team will administer the new treatment as an adjunct to the current standard-of-care treatment of amputation and (carboplatin) chemotherapy to help prevent the cancer from spreading to other organs. Despite treatment, approximately 85 to 90 percent of canine patients succumb to metastatic disease within two years of diagnosis with osteosarcoma. An effective, new treatment would be a major breakthrough in the fight against this aggressive and terminal cancer in dogs.

Study ID
D17CA-501
Study Status
Complete
Start Date
10/01/2017
Grant amount awarded
$747,968
Grant recipient
University of Pennsylvania
Study country
United States
Investigator
Nicola J. Mason, BVetMed, PhD
Study category
Cancer